Verndari was founded with the goal to eliminate needle phobia and the need for the cold chain with a cost-effective simple-to-use vaccination kit that can be mass produced.Verndari is focused on the influenza vaccine. THey have developed a new method for making the influenza vaccine antigen in mammalian cells. This presentation of the influenza vaccine allows the use of the FDA approved surrogate markers of potency and efficacy. These surrogate markers enable rapid development of manufacturing capacity and rapid clinical trial demonstration of efficacy. This new method of influenza vaccine antigen production coupled with the high-volume automated production of a room temperature stable single-dose vaccination kit may enable a rapid response platform capable of addressing pandemic biological threats.

Medigen Biotechnology was established at the end of 1999. The company adheres to the vision of “Innovation makes life better” and focuses on the development of new products in the two major areas of “hepatopathy” and “cancer” in Asia. Through years of hard work, Keya Biotech has gradually developed into a comprehensive biopharmaceutical group, and its business has covered: new drug clinical development, innovative biomedical research and development platform, molecular detection, cell culture vaccine technology, and scientific name drug production and marketing. And many other businesses.

Bullet Biotechnology, Inc. develops active immunotherapies to stimulate a person’s own immune system to overcome diseases. Its technology educates the immune system to targeting specific cells that are causing disease. The firm's pipeline includes therapeutic vaccines for cancer, multi-specific antibody capsid products, therapeutic vaccines for autoimmune diseases, and other vaccines. The company was founded by Diego Fonstad, James R. Swartz, Willie Quinn and Thomas Theriault in September 2011 and is headquartered in Redwood City, CA.

Jiangsu Jinpu Nuoan Biotechnology Co., Ltd., established on 2012-03-29, The business scope includes gene recombinant protein drugs,Research and development of vaccines and enzymes;Production,Sales of enzyme preparations for biomedicine(Operating with a license involving a license);Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) General project:Production of Class I Medical Devices;Sales of Class I Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Tiankang Pharmaceutical (Suzhou) Co., Ltd., established on 2018-03-22, Business scope includes licensed projects:Veterinary drug production;Veterinary drug business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Zhongnong Weite Biotechnology Co., Ltd., established on 2003-06-23, Business scope includes veterinary biological products(vaccine,diagnostic fluid),Veterinary vaccine adjuvants and immune enhancers,Production of Chinese and Western veterinary medicines and feed veterinary pharmaceutical additives,Wholesale and retail;Biotechnology,Research and development of pharmaceutical equipment and veterinary equipment,Promotion and technology transfer;Training and consulting services for the above-mentioned related businesses;Self-operated and agent import and export business of various commodities and technologies(Except for items restricted and prohibited by the country).(Any project involving administrative licensing or qualification,with a valid license,Qualification certificate operation)

Shanghai Zerun Biotechnology Co., Ltd. engages in the development, commercialization, and industrialization of new recombinant human vaccine products. It develops recombinant vaccines such as preventive cervical cancer vaccines, and recombinant enterovirus 71 virus-like particle and therapeutic vaccines. The company was founded on May 7, 2003 and is headquartered in Shanghai, China.

PaxVax is a vaccine start-up company developing candidate oral vaccines for influenza, and key infectious diseases. It has developed a proprietary oral vaccine technology based on a common virus called adenovirus. The technology removes the delivery hurdles of traditional injectable vaccines, namely the need for cold storage, needles, and administration by medical personnel. PaxVax was founded in 2007 and is headquartered in Gaithersburg, Maryland.

Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.

Shandong Lvdu Biotechnology Co., Ltd., established on 2006-03-07, Business scope includes licensed projects:Veterinary drug production;Veterinary drug business;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Inspection and testing service;Production of disinfection products for the prevention and control of infectious diseases;pharmaceutical production;Drug import and export;Livestock raising;Breeding livestock and poultry production;publication retail.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Livestock Machinery Manufacturing;Livestock Machinery Sales;Manufacturing of experimental analysis instruments;glassware manufacturing;Instrument Manufacturing;Experimental analysis instrument sales;Instrument sales;Manufacturing of other general instruments;Business Management Consulting;Financial Advisory;Bill Information Consulting Service;Information Consulting Service(Not including licensing information consulting services);Educational Consulting Services(Education and training activities that do not include licensing approval);Medical Research and Experimental Development;Specialty Chemicals Sales(Free of Hazardous Chemicals);Research and development of bio-based materials technology;Engineering and Technology Research and Experimental Development;Sales of bio-based materials;R&D of industrial enzyme preparations;Extraction of marine bioactive substances,purification,Synthesis technology research and development;R&D and application of cell technology;Fermentation process optimization technology research and development;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Internet of Things Technology Services;Technology Import and Export;Import and export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Chongqing Bylord Biological Products Co., Ltd., established on 2012-05-21, Business scope includes biological products,biologics,biological vaccine,medical supplements,R&D of drug intermediates,production and sales(Does not contain drugs,Intermediates of Narcotics and Psychotropic Drugs);import and export trade;Technical consulting and transfer services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)***

TechnoVax is a privately held near-clinical-stage biotechnology company based in Tarrytown, NY specializing in viral vaccine development. Our mission is to create and advance towards the market safe, unique and novel vaccine technologies with no current alternatives that will revolutionize the way vaccines are developed, distributed and administered. TechnoVax has developed a next-generation technology-platform based on Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. The industry strongly believes that VLP based vaccines is the technology of the future! Our vaccines pipeline has been rapidly approaching the clinical phases with 3 main candidates: A Universal flu vaccine that will eliminate the need for annual flu vaccination and will protect faster and better against future pandemic strains; an Inhaled Powder flu vaccine that eliminates the need for cold chain storage and distribution and could be self-administered: a greatly needed solution for the developing world; and an RSV vaccine to protect against one of the leading causes of infant and elderly hospitalizations and often results in fatalities with the elderly. We are supported by a strong network of industry, governmental agencies and academic collaborators and have received over $5.0 million in equity and non-dilutive funding (NIH, IRS grants and programs). Our portfolio of vaccine candidates has a prospective addressable market of over US$5 billion in annual worldwide sales. Our IP is strong and protected by multiple domestic and international patent applications. We are actively pursuing strategic alliances, licensing arrangements and collaborations in order to bring our products closer to the market. We are seeking funding to start human testing of 1 to 3 vaccine candidates.

China Animal Husbandry Industry Co., Ltd. engages in the research and development, production, sale, and service of animal health and nutrition products. Its products and services include animal health products, veterinary medicine, veterinary vaccine, daily products, food, pet products, bulk raw materials, and additive. The company was founded on December 25, 1998 and is headquartered in Beijing, China.

Zhejiang Hilong Biotechnology Co., Ltd., established on 2012-11-06, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology Import and Export;Sales of Class II Medical Devices;Conference and Exhibition Services;Domestic trade agent;Inspection business;Health Consulting Services(Does not include medical services);pet service(No Animal Treatment)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Veterinary drug production;Animal Clinic;Pharmaceutical commissioned production;Veterinary drug business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Harbin Veken Biotechnology Co., Ltd., established on 1992-10-27, The scope of business includes the development of bioengineering technology and products,Production,Sales and Technical Consulting,Technical Services;Sales of ancillary products related to development projects(Products not subject to country restrictions);Engage in import and export business within the scope approved by the import and export enterprise qualification certificate;Car rental;Technology Development for Livestock Raising;Technical Services for Laboratory Animals;Sales:birds,Egg,Agricultural and sideline products.Experimental animal management;animal husbandry;Animal epidemic prevention;Food production and operation;Veterinary drug business.The following are limited to branch operations:Diagnosis and treatment of animal diseases.

Novartis Biotechnology (Wuhan) Co., Ltd., established on 2009-03-30, Business scope includes technology development in the field of biotechnology,technical consulting,Technology transfer and service;Biological product(remove human stem cells,Development and application of genetic diagnosis and treatment technology),Development of In Vitro Detection Kit;Technology import and export business.(The above business scope does not involve special management measures for foreign investment access;Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Changchun BCHT Biotechnology Co. engages in the research and development, production and sale of human vaccines. It specializes in prevention and treatment of infectious diseases. Its products include chickenpox vaccine, rabies vaccine, and freeze-dried nasal spray flu vaccine. The company was founded on March 4, 2004 and is headquartered in Changchun, China.